Scarica l'app Stockscreener
14.71
2.23%
-0.325
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché AUPH Giù?
Forum
Previsione
Frazionamento azionario
Aurinia Pharmaceuticals Inc Borsa (AUPH) Ultime notizie
Aurinia Pharmaceuticals (NASDAQ:AUPH) Director Buys $7,224,981.61 in Stock - MarketBeat
Aurinia Pharmaceuticals Inc (AUPH): Investor Outlook Reveals 19.63% Potential Upside - DirectorsTalk Interviews
Tang Capital LPs tied to Aurinia (NASDAQ: AUPH) buy 900K shares - Stock Titan
Tang Capital boosts Aurinia (AUPH) stake to 9.2% ownership - Stock Titan
Aurinia (NASDAQ: AUPH) CFO gets stock, options; covers tax bill - Stock Titan
Aurinia (AUPH) COO receives stock grants and settles taxes with shares - Stock Titan
Aurinia (NASDAQ: AUPH) CEO receives major option grant and withholds shares for taxes - Stock Titan
Aurinia (AUPH) CMO awarded new stock options and share grant - Stock Titan
Aurinia (AUPH) EVP gets stock awards and has shares withheld for taxes - Stock Titan
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Passes Key Growth Screener from "The Little Book That Makes You Rich" - ChartMill
GSA Capital Partners LLP Trims Stake in Aurinia Pharmaceuticals Inc $AUPH - MarketBeat
Should Aurinia’s Surging 2025 Earnings and Upbeat 2026 Outlook Require Action From Aurinia (AUPH) Investors? - Yahoo Finance
Aurinia’s LUPKYNIS Strength And Aritinercept Progress Versus Valuation Signals - Sahm
Aurinia Pharmaceuticals (AUPH) Reports Financial Results for Three and Twelve Months Ended December 31, 2025 - Bitget
Understanding the Setup: (AUPH) and Scalable Risk - Stock Traders Daily
12 Cheap Biotech Stocks to Buy Now - Insider Monkey
How Aurinia Pharmaceuticals Inc. stock trades during market volatilityWeekly Trade Review & AI Driven Stock Movement Reports - mfd.ru
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q4 2025 Earnings Call Transcript - Insider Monkey
Aurinia Pharmaceuticals (AUPH) Earnings Spike Above Revenue Challenges Profit Quality Narratives - Sahm
Decoding Aurinia Pharmaceuticals Inc (AUPH): A Strategic SWOT In - GuruFocus
Aurinia Pharmaceuticals Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Aurinia Pharmaceuticals (NASDAQ:AUPH) Posts Earnings Results - MarketBeat
Aurinia Pharmaceuticals (AUPH) Stock Drops After Strong Quarter, Softer Forward Revenue Targets - Fidelity
Aurinia Pharmaceuticals Q4 Earnings Call Highlights - Yahoo Finance
AUPH: LUPKYNIS posted robust 2025 growth, with 2026 guidance reflecting continued momentum and market expansion - TradingView
Earnings call transcript: Aurinia Pharmaceuticals Q4 2025 earnings beat expectations - Investing.com
AUPH: LUPKYNIS sales and net income surged in 2025, with double-digit growth expected in 2026 - TradingView
Aurinia Pharmaceuticals : Corporate Presentation (Aurinia Corporate Presentation February 2026) - marketscreener.com
Aurinia Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Aurinia Results Highlight LUPKYNIS Momentum And New Aritinercept Growth Option - Yahoo Finance
Earnings Breakdown: Aurinia Pharmaceuticals Q4 - Benzinga
Q4 2025 Earnings Call - marketscreener.com
Aurinia Pharmaceuticals (AUPH) Tops Q4 Earnings and Revenue Estimates - Yahoo Finance
Aurinia Pharmaceuticals Inc. Provides Earnings Guidance for the Year 2026 - marketscreener.com
AUPH Stock Gains On Aurinia Pharma’s Q4 Beat, But 2026 Guidance Misses Estimates - Stocktwits
Aurinia Lifts Revenue on LUPKYNIS Growth, Sets Strong 2026 Sales Outlook - TipRanks
Aurinia Pharmaceuticals Q4 Earnings, Revenue Rise; 2026 Revenue Outlook Set - marketscreener.com
AUPH: LUPKYNIS sales and net income soared in 2025, with strong growth and robust 2026 guidance - TradingView
Aurinia Lifts Profits on LUPKYNIS Growth and Sets Double-Digit 2026 Revenue Outlook - TipRanks
AURINIA PHARMACEUTICALS ($AUPH) Releases Q4 2025 Earnings - Quiver Quantitative
(AUPH) Aurinia Pharmaceuticals Expects Full Year 2026 Revenue Range $315M$325, vs. FactSet Est of $326.8M - marketscreener.com
Earnings Flash (AUPH) Aurinia Pharmaceuticals Posts Q4 EPS $1.53 - marketscreener.com
Earnings Flash (AUPH) Aurinia Pharmaceuticals Inc. Reports Q4 Revenue $77.1M, vs. FactSet Est of $74.7M - marketscreener.com
Aurinia Pharmaceuticals Inc announces its financial results for the fourth quarter and full year ended December 31, 2025 - Bitget
Aurinia Pharmaceuticals Inc. SEC 10-K Report - TradingView
Aurinia: Q4 Earnings Snapshot - marketscreener.com
Form 10-K Aurinia Pharmaceuticals For: Dec 31 - StreetInsider
Profit surge as Aurinia (NASDAQ: AUPH) raises 2026 LUPKYNIS outlook - Stock Titan
Earnings Summary: Aurinia Pharmaceuticals Q4 - Benzinga
Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provides Update on Recent Business Progress - marketscreener.com
BRIEF-Aurinia Pharmaceuticals Q4 Product Revenue USD 74.173 Million - TradingView
Aurinia Pharmaceuticals Inc (AUPH) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... By GuruFocus - Investing.com Canada
Earnings Preview: Aurinia Pharmaceuticals - Benzinga
Aurinia earnings on deck: Can lupus drug sustain growth momentum? By Investing.com - Investing.com Australia
Aurinia Pharmaceuticals (AUPH) Stock Analysis: A Look At Its 12.38% Potential Upside - DirectorsTalk Interviews
Aurinia Pharmaceuticals Inc expected to post earnings of 22 cents a shareEarnings Preview - TradingView
MSN Money - MSN
Aurinia (AUPH) COO has 32,901 shares withheld to cover RSU taxes - Stock Titan
Aurinia (AUPH) CEO Greenleaf has 100,171 shares withheld for RSU taxes - Stock Titan
Tax withholding trims Aurinia (AUPH) CFO stake by 32,424 shares - Stock Titan
[Form 4] Aurinia Pharmaceuticals Inc. Insider Trading Activity - Stock Titan
Jupiter Asset Management Ltd. Has $9.10 Million Stake in Aurinia Pharmaceuticals Inc $AUPH - MarketBeat
Aurinia Sets February 26 Date to Report 2025 Results and Business Update - TipRanks
Aurinia Pharmaceuticals Inc (AUPH) has announced that it will release its financial results for the fourth quarter and full year ended December 31, 2025, on February 26, 2026. - Bitget
Aurinia Pharmaceuticals to Report Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provide Update on Recent Business Progress on February 26, 2026 - ChartMill
Aurinia Pharmaceuticals (AUPH) Projected to Post Quarterly Earnings on Thursday - MarketBeat
4.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):